Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
17
09
2023
medline:
24
11
2023
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
Solriamfetol (SUNOSI Excessive daytime sleepiness (EDS) is a common condition in which an individual is unable to stay awake during periods when they typically would be awake. Dopamine and norepinephrine are among the chemical messengers involved in sleep–wake regulation. Solriamfetol (SUNOSI
Autres résumés
Type: plain-language-summary
(eng)
Excessive daytime sleepiness (EDS) is a common condition in which an individual is unable to stay awake during periods when they typically would be awake. Dopamine and norepinephrine are among the chemical messengers involved in sleep–wake regulation. Solriamfetol (SUNOSI
Identifiants
pubmed: 37847434
doi: 10.1007/s40263-023-01040-5
pii: 10.1007/s40263-023-01040-5
doi:
Substances chimiques
solriamfetol
939U7C91AI
Carbamates
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1009-1020Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Pérez-Carbonell L, Mignot E, Leschziner G, et al. Understanding and approaching excessive daytime sleepiness. Lancet. 2022;400(10357):1033–46.
doi: 10.1016/S0140-6736(22)01018-2
pubmed: 36115367
Lal C, Weaver TE, Bae CJ, et al. Excessive daytime sleepiness in obstructive sleep apnea: mechanisms and clinical management. Ann Am Thorac Soc. 2021;18(5):757–68.
doi: 10.1513/AnnalsATS.202006-696FR
pubmed: 33621163
pmcid: 8086534
Ono T, Takenoshita S, Nishino S. Pharmacologic management of excessive daytime sleepiness. Sleep Med Clin. 2022;17(3):485–503.
doi: 10.1016/j.jsmc.2022.06.012
pubmed: 36150809
Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367–76.
doi: 10.1124/jpet.118.248120
pubmed: 29891587
TMC Pharma (EU) Ltd. Sunosi (solriamfetol) film-coated tablets: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi . Accessed 6 Sep 2023.
Axsome Therapeutics Inc. SUNOSI (solriamfetol) tablets, for oral use: US prescribing information. 2023. https://www.fda.gov/ . Accessed 6 Sep 2023.
Markham A. Solriamfetol: first global approval. Drugs. 2019;79(7):785–90.
doi: 10.1007/s40265-019-01123-y
pubmed: 31062265
Deeks ED, Heo YA. Solriamfetol in excessive daytime sleepiness: a profile of its use. Drugs Ther Perspect. 2020;36(5):173–80.
doi: 10.1007/s40267-020-00720-2
Zomorodi K, Chen D, Lee L, et al. A randomized, double-blind, placebo- and positive-controlled, 4-period crossover study of the effects of solriamfetol on QTcF intervals in healthy participants. Clin Pharmacol Drug Dev. 2021;10(4):404–13.
doi: 10.1002/cpdd.867
pubmed: 32935460
Carter LP, Henningfield JE, Wang YG, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351–61.
doi: 10.1177/0269881118796814
pubmed: 30269642
pmcid: 6247449
Zomorodi K, Chen D, Lee L, et al. Single-dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019;59(8):1120–9.
doi: 10.1002/jcph.1402
pubmed: 30865315
pmcid: 6618134
Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102–8.
doi: 10.1016/j.sleep.2015.05.013
pubmed: 26298786
Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379–87.
doi: 10.5665/sleep.5968
pubmed: 27166238
pmcid: 4909620
Strollo PJ Jr, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019;155(2):364–74.
doi: 10.1016/j.chest.2018.11.005
pubmed: 30471270
Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–70.
doi: 10.1002/ana.25423
pubmed: 30694576
pmcid: 6593450
Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2019;199(11):1421–31.
doi: 10.1164/rccm.201806-1100OC
pubmed: 30521757
pmcid: 6835071
Malhotra A, Shapiro C, Pepin JL, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep. 2020;43(2):1–11.
doi: 10.1093/sleep/zsz220
European Medicines Agency. Sunosi (international non-proprietary name solriamfetol): EU assessment report. 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi . Accessed 6 Sep 2023.
Krystal AD, Benca RM, Rosenberg R, et al. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. J Psychiatr Res. 2022;155:202–10.
doi: 10.1016/j.jpsychires.2022.08.018
pubmed: 36070638
pmcid: 9718635
Dauvilliers Y, Shapiro C, Mayer G, et al. Solriamfetol for the treatment of excessive daytime sleepiness in participants with narcolepsy with and without cataplexy: subgroup analysis of efficacy and safety data by cataplexy status in a randomized controlled trial. CNS Drugs. 2020;34(7):773–84.
doi: 10.1007/s40263-020-00744-2
pubmed: 32588401
Emsellem HA, Thorpy MJ, Lammers GJ, et al. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. Sleep Med. 2020;67:128–36.
doi: 10.1016/j.sleep.2019.11.1250
pubmed: 31926465
Schweitzer PK, Mayer G, Rosenberg R, et al. Randomized controlled trial of solriamfetol for excessive daytime sleepiness in OSA: an analysis of subgroups adherent or nonadherent to OSA treatment. Chest. 2021;160(1):307–18.
doi: 10.1016/j.chest.2021.02.033
pubmed: 33631141
pmcid: 8411452
Weaver TE, Drake CL, Benes H, et al. Effects of solriamfetol on quality-of-life measures from a 12-week phase 3 randomized controlled trial. Ann Am Thorac Soc. 2020;17(8):998–1007.
doi: 10.1513/AnnalsATS.202002-136OC
pubmed: 32353246
pmcid: 7393785
Schweitzer PK, Strohl KP, Mayer G, et al. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. J Clin Sleep Med. 2021;17(4):659–68.
doi: 10.5664/jcsm.8992
pubmed: 33179591
pmcid: 8020710
Weaver TE, Pepin JL, Schwab R, et al. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021;17(10):1995–2007.
doi: 10.5664/jcsm.9384
pubmed: 34606437
pmcid: 8494093
Winter Y, Mayer G, Kotterba S, et al. Solriamfetol real world experience study (SURWEY): initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany. Sleep Med. 2023;103:138–43.
doi: 10.1016/j.sleep.2023.01.022
pubmed: 36796288
Malhotra A, Strollo PJ, Pepin J-L, et al. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. Sleep Med. 2022;100:165–73.
doi: 10.1016/j.sleep.2022.08.005
pubmed: 36084494
pmcid: 9669231
Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28(9):2815–30.
doi: 10.1111/ene.14888
pubmed: 34173695
Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–93.
doi: 10.5664/jcsm.9328
pubmed: 34743789
pmcid: 8636351
Gandhi KD, Mansukhani MP, Silber MH, et al. Excessive daytime sleepiness: a clinical review. Mayo Clin Proc. 2021;96(5):1288–301.
doi: 10.1016/j.mayocp.2020.08.033
pubmed: 33840518
Bioprojet Pharma. Wakix (pitolisant) film-coated tablets: EU summary of product characteristics. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/wakix . Accessed 6 Sep 2023.
UCB Pharma SA. Xyrem (sodium oxybate) 500 mg/mL oral solution: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem . Accessed 6 Sep 2023.
European Medicines Agency. Modafinil-containing medicinal products: annex I, II, III, IV. 2011. https://www.ema.europa.eu/en/medicines/human/referrals/modafinil . Accessed 6 Sep 2023.
Teva Pharmaceuticals USA Inc. PROVIGIL
Jazz Pharmaceuticals Inc. XYREM
Harmony Biosciences LLC. WAKIX
Teva Pharmaceuticals USA Inc. NUVIGIL
Rosenberg R, Schweitzer PK, Steier J, et al. Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management. Postgrad Med. 2021;133(7):772–83.
doi: 10.1080/00325481.2021.1948305
pubmed: 34292843
Randerath W, Verbraecken J, de Raaff CAL, et al. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. Eur Respir Rev. 2021;30(162): 210200.
doi: 10.1183/16000617.0200-2021
pubmed: 34853097
pmcid: 9489103
Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263–76.
doi: 10.5664/jcsm.27497
pubmed: 19960649
Bioprojet Pharma. Ozawade (pitolisant) film-coated tablets: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade . Accessed 6 Sep 2023.
Pitre T, Mah J, Roberts S, et al. Comparative efficacy and safety of wakefulness-promoting agents for excessive daytime sleepiness in patients with obstructive sleep apnea: a systematic review and network meta-analysis. Ann Intern Med. 2023;176(5):676–84.
doi: 10.7326/M22-3473
pubmed: 37155992
Zhan S, Ye H, Li N, et al. Comparative efficacy and safety of multiple wake-promoting agents for the treatment of excessive daytime sleepiness in narcolepsy: a network meta-analysis. Nat Sci Sleep. 2023;15:217–30.
doi: 10.2147/NSS.S404113
pubmed: 37082610
pmcid: 10112483
Chien PY, Kuo CY, Lin MH, et al. Pharmacological interventions for excessive daytime sleepiness in adults with narcolepsy: a systematic review and network meta analysis. J Clin Med. 2022;11(21):6302.
doi: 10.3390/jcm11216302
pubmed: 36362535
pmcid: 9654433
Ronnebaum S, Bron M, Patel D, et al. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. J Clin Sleep Med. 2021;17(12):2543–55.
doi: 10.5664/jcsm.9610
pubmed: 34402784
pmcid: 8726370